Dasotraline
- Generic Name
- Dasotraline
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15Cl2N
- CAS Number
- 675126-05-3
- Unique Ingredient Identifier
- 4D28EY0L5T
- Background
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03231800
- Locations
- ๐บ๐ธ
Avida Inc, Newport Beach, California, United States
๐บ๐ธQps-Mra, Llc, South Miami, Florida, United States
๐บ๐ธSouth Shore Psychiatric Services PC, Hingham, Massachusetts, United States
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
- Conditions
- Binge Eating Disorder
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 491
- Registration Number
- NCT03107026
- Locations
- ๐บ๐ธ
Lytle and Weiss PLLC, Denver, Colorado, United States
๐บ๐ธClinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
๐บ๐ธBioscience Research, LLC, Mount Kisco, New York, United States
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)Binge-Eating Disorder Disorder
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02795637
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT02734693
- Locations
- ๐บ๐ธ
Avida Inc, Newport Beach, California, United States
๐บ๐ธMeridien Research, Bradenton, Florida, United States
๐บ๐ธBayou City Research, Ltd, Houston, Texas, United States
Dasotraline Binge Eating Disorder Extension Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 533
- Registration Number
- NCT02684279
- Locations
- ๐บ๐ธ
Neuotrials Research, Inc., Atlanta, Georgia, United States
๐บ๐ธBoston Clinical Trials, Boston, Massachusetts, United States
๐บ๐ธTexas Center for Drug Development, Inc., Houston, Texas, United States
Dasotraline Binge Eating Disorder Study
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT02564588
- Locations
- ๐บ๐ธ
PCSD- Feighner Research, San Diego, California, United States
๐บ๐ธCapstone Clinical Research, Libertyville, Illinois, United States
๐บ๐ธSunstone Medical Research, LLC, Medford, Oregon, United States
Dasotraline Pediatric Extension Study
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02457819
- Locations
- ๐บ๐ธ
Psychiatric Associates, Overland Park, Kansas, United States
๐บ๐ธHarmonex Neuroscience Research, Inc, Dothan, Alabama, United States
๐บ๐ธClinical Trials group at the Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Dasotraline Pediatric ADHD Study
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02428088
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research, Fort Myers, Florida, United States
๐บ๐ธNeurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States
๐บ๐ธHarmonex Neuroscience Research, Dothan, Alabama, United States
Dasotraline Adult ADHD Study
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT02276209
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research, Fort Myers, Florida, United States
๐บ๐ธKennedy Krieger Institute, Baltimore, Maryland, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Dasotraline SEP360-105 Pediatric PK/PD Study
- Conditions
- Pediatric Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02195167
- Locations
- ๐บ๐ธ
MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States
๐บ๐ธPalm Springs Research Institute, Hialeah, Florida, United States
๐บ๐ธiResearch Atlanta, LLC, Decatur, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.